The much-anticipated Drug, Chemical & Associated Technologies (DCAT) Week in New York City is around the corner, and Syngene is excited to be participating.
Syngene is a global CRO/CDMO equipped with end-to-end capabilities across the drug discovery, development, and manufacturing lifecycle. In small molecule development, we offer expertise in process R&D, chemical development, formulation development, analytical development, clinical development, and API commercial manufacturing (70,000L capacity). We also offer a sterile fill-finish facility for clinical supplies.
In biologics, we have expertise in recombinant proteins, glycoproteins, mAbs, antibody fragments, bispecfics, and microbiomes (live biotherapeutics). We have an installed biologics drug substance manufacturing capacity of 28,000L. We also offer a commercial-scale, high-speed sterile fill-finish facility for biologics manufacturing.
Our senior leadership team will be available to discuss your challenges and how Syngene can help you advance your R&D programs. Participating experts include CEO and MD Jonathan Hunt; Senior VP, Manufacturing Alex Del Priore; Head of Sales, Development, and Manufacturing Ian Grundy; VP of Business Development, Clinical Nageswara Rao; and Director, Business Development, Biologics Pravin Prajapati.
Don’t miss this opportunity to learn how we offer first-time-right technology transfers, accelerated development timelines, and cost efficiencies.